Jeffrey Wolf, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jeffrey Wolf, MD

Clinical Professor, Department of Medicine, UCSF; and Director, Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-2421 (appts)
Box 0324, UCSF, San Francisco, CA 94143-0324

View on UCSF Profiles

Cancer Center Membership

Associate Member » Hematopoietic Malignancies

Education

Washington University; St. Louis, Missouri, A.B., 1968, Chemistry
University of Illinois Medical Center, Chicago, IL, M.D., 1972
University of California, San Diego, Intern, 1972-1973, Internal Medicine
University of California, San Diego, Residency, 1973-1974, Internal Medicine
University of California, San Diego, Residency, 1975-1976, Internal Medicine
Fred Hutchinson Cancer Research Center, Seattle, Washington, Fellowship, January-February, 1977, Bone Marrow Transplantation
University of California San Francisco, San Francisco, Fellowship, 1976-1979, Hematology/Oncology


Professional Experience

  • 1979-1982
    Staff Physician, City of Hope National Medical Center, Duarte, California, Hematology and Bone Marrow Transplantation
  • 1982-2007
    Director of Stem Cell Transplantation Program, Practice of Hematology and Oncology, Alta Bates Summit Medical Center, Berkeley, California
  • 2007-present
    Clinical Professor of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California
  • 2007-2010
    Director, Clinical Research, Division of Hematology/Oncology, University of California, San Francisco, California
  • 2007-present
    Director, Myeloma Program, Division of Hematology/Oncology, University of California, San Francisco, California

Honors & Awards

  • 1968-1972
    Bamberger Scholarship, University of Illinois, School of Medicine

Selected Publications

  1. Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5.
    View on PubMed
  2. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 Mar 1.
    View on PubMed
  3. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KM, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb 16.
    View on PubMed
  4. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-Term Outcomes of Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with Autologous Hematopoietic Cell Transplant in First Complete Remission. Leuk Lymphoma. 2015 Oct 22; 1-20.
    View on PubMed
  5. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  6. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91.
    View on PubMed
  7. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  8. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3.
    View on PubMed
  9. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
    View on PubMed
  10. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6.
    View on PubMed
  11. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010; 3:9.
    View on PubMed
  12. Layzer R, Wolf J. Myeloma-associated polyneuropathy responding to lenalidomide. Neurology. 2009 Sep 8; 73(10):812-3.
    View on PubMed
  13. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009 Sep; 146(6):619-26.
    View on PubMed
  14. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 Jun; 129(6):776-83.
    View on PubMed
  15. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301.
    View on PubMed
  16. Govberg IJ, Wolf JL, Cotter PD. Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genet Cytogenet. 2000 Sep; 121(2):212-5.
    View on PubMed
  17. Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
    View on PubMed
  18. McGhee EM, Cohen NR, Wolf JL, Ledesma CT, Cotter PD. Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2000 Apr 15; 118(2):163-6.
    View on PubMed
  19. Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant. 2000; 6(5):496-505.
    View on PubMed
  20. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
    View on PubMed

Go to UCSF Profiles, powered by CTSI